FDAsafety guidance66% confidence
FDA AP — MYCOPHENOLATE MOFETIL (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Hikma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA065413. Sponsor: HIKMA. Submission status: AP. Submission type: SUPPL. Active ingredients: MYCOPHENOLATE MOFETIL.
Supporting Context
- Therapeutic area
- Immunology · Immunosuppressant
- Sub-indication
- General
Related signal: FDA Approval Update for Mycophenolate Mofetil by Hikma